-
Apparently,
#chrsparks is being a "nuble" according to@AprilRolin -
#Prostatecancer is the 4th most common#cancer worldwide.#patients &#physicians are eagerly awaiting data from Novartis/Endocyte’s Ph 3 trial of Lutetium-177 PSMA-617. In our blog we discuss how this could change#prostatecancer care: https://bit.ly/2S32qPm#CHRsparks#CHRpic.twitter.com/IANP3FwhBG
-
Have you seen our latest
#CHRsparks post on#LinkedIn? https://bit.ly/2ro1g7s Our#team attended the#ACR Annual Meeting in#Atlanta. Read the team's views and#analysis of the#conference and the evolving axSpA (axial Spondyloarthritis)#landscape.#Consulting#TeamCHR#ACR19pic.twitter.com/M6ZDx4hS7a
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.